Prostate Cancer News and Research

RSS

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Genetic biomarker test could help personalize therapy for men with high-risk prostate cancer

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.

26 Oct 2021

Scientists discover a new enzymatic complex that can halt cells from aging

Researchers at Université de Montréal and McGill University have discovered a new multi-enzyme complex that reprograms metabolism and overcomes “cellular senescence,” when aging cells stop dividing.

17 Sep 2021

New approach to identify molecular targets for improved prostate cancer therapy

In a new study, researchers have introduced DSER, a technique for identifying molecular targets for enhanced therapy in prostate cancer.

14 Sep 2021

Researchers identify inhibitor that converts immune cold cancer to red hot ones

Scientists headed by the University of Michigan Rogel Cancer Center converted an immune cold cancer into one that responds to immunotherapy.

4 Aug 2021

Study unravels the biomechanical, biophysical response of cancer cells to drugs

A new study reports the use of single-cell, force spectroscopy methods to probe biophysical and biomechanical kinetics of cancer cells.

21 Jul 2021

Atomic force spectroscopy probes cellular biomechanics in response to drugs in hypoxia

Oncotarget published "Dynamic cellular biomechanics in responses to chemotherapeutic drug in hypoxia probed by atomic force spectroscopy" which reported that by exploiting single-cell, force spectroscopy methods, the authors probed biophysical and biomechanical kinetics of brain, breast, prostate, and pancreatic cancer cells with standard chemotherapeutic drugs in normoxia and hypoxia over 12-24 hours.

20 Jul 2021

Carrying out CRISPR/Cas9 in Space

In our latest interview, AZoLifeSciences spoke to a team of researchers about their latest research which involved carrying out CRISPR/Cas9 in Space.

8 Jul 2021

New study on genotype-phenotype associations sheds light on human complex traits, diseases

A new study analyzing the association between an individual's genetics (genotype) and their observable characteristics resulting from the interaction of genetics and the environment (phenotype), contributes new knowledge to the understanding of human complex traits and diseases.

2 Jun 2021

Researchers study the mechanical properties of prostate cancer cells treated with anti-cancer drugs

Malignant tumor cells undergo mechanical deformation more easily than normal cells, allowing them to migrate throughout the body. The mechanical properties of prostate cancer cells treated with the most commonly used anti-cancer drugs have been investigated at the Institute of Nuclear Physics of the Polish Academy of Sciences in Cracow.

28 May 2021

Researchers suggest new strategies for finding drugs that neutralize key enzymes

Scientists from the UK's University of Bath explore racemases - an important type of enzyme that is linked to certain cancers and other life-threatening diseases while also being critical to cell function - in a paper published in the prestigious journal Chemical Society Reviews. The scientists also propose new strategies for finding drugs that neutralize these enzymes.

From University of Bath 26 May 2021

Hormone drugs may help disarm coronavirus spike protein and stop disease progression

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.

23 Mar 2021

Study reveals mechanism by which ibuprofen prevents RAC1B alternative splicing in colorectal cells

Oncotarget published "Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein complex required for expression of tumor-related splicing variant RAC1B in colorectal cells" which reported that although the molecular mechanism behind the antitumor properties of NSAIDs has been largely attributed to inhibition of cyclooxygenases , several studies have shown that the chemopreventive properties of ibuprofen also involve multiple COX-independent effects.

23 Mar 2021

Adhesion strength and contractility enable metastatic cancer cells to display adurotactic behavior

Bioengineers at the University of California San Diego and San Diego State University have discovered a key feature that allows cancer cells to break from typical cell behavior and migrate away from the stiffer tissue in a tumor, shedding light on the process of metastasis and offering possible new targets for cancer therapies.

From UC San Diego 10 Mar 2021

Amazing possibilities of using artificial intelligence in pathology

Artificial intelligence can already scan images of the eye to assess patients for diabetic retinopathy, a leading cause of vision loss, and to find evidence of strokes on brain CT scans.

9 Mar 2021

Genomic test helps identify prostate cancer patients who may benefit from hormone therapy

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

12 Feb 2021

Drug-resistant, metastasis-causing cells produce exponentially growing tumors

The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.

27 Jan 2021

Prostate Cancer News and Research

Genetic biomarker test could help personalize therapy for men with high-risk prostate cancer

Scientists discover a new enzymatic complex that can halt cells from aging

New approach to identify molecular targets for improved prostate cancer therapy

Researchers identify inhibitor that converts immune cold cancer to red hot ones

Study unravels the biomechanical, biophysical response of cancer cells to drugs

Atomic force spectroscopy probes cellular biomechanics in response to drugs in hypoxia

Carrying out CRISPR/Cas9 in Space

New study on genotype-phenotype associations sheds light on human complex traits, diseases

Researchers study the mechanical properties of prostate cancer cells treated with anti-cancer drugs

Researchers suggest new strategies for finding drugs that neutralize key enzymes

Hormone drugs may help disarm coronavirus spike protein and stop disease progression

Study reveals mechanism by which ibuprofen prevents RAC1B alternative splicing in colorectal cells

Adhesion strength and contractility enable metastatic cancer cells to display adurotactic behavior

Amazing possibilities of using artificial intelligence in pathology

Genomic test helps identify prostate cancer patients who may benefit from hormone therapy

Drug-resistant, metastasis-causing cells produce exponentially growing tumors

New study explores the role of genetics in prostate cancer

Chromosomal instability is associated with cancer's aggressiveness

Study explains new associations between Neanderthal DNA and autoimmune diseases

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics